Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-hodgkin's lymphoma patients treated with chemotherapy

Value in Health

Volumn 14, Issue 2, 2011, Pages 253-262

  Gruschkus, Stephen K ^a   Lairson, David ^a   Dunn, J Kay ^a   Risser, Jan ^a   Du, Xianglin L ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cancer; Cost effectiveness; Granulocyte colony stimulating factors; Non Hodgkin's lymphoma; Outcomes research

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; DNA TOPOISOMERASE INHIBITOR; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; VINCA ALKALOID;

AGED; ARTICLE; CANCER PATIENT; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICARE; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REIMBURSEMENT; TREATMENT OUTCOME;

EID: 79959582386     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.09.010     Document Type: Article

References (43)

1. American Cancer Society Cancer Facts and Figures 2008. Available from: Www.cancer.org. [Accessed December 21, 2008].
2. National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Cancer Statistics Review, 1975-2004. 2007. Available from: Http://seer.cancer.gov/ csr/1975-2004/sections.html. [Accessed December 21, 2008].
3. Crawford J, Dale D, Lyman GH. Suboptimal dosing in adjuvant breast cancer chemotherapy: Evidence from a nationwide survey. Breast Cancer Res Treat 2000;64:66.
4. Lyman GH, Crawford J, Dale D, et al. Clinical prediction models for febrile neutropenia and relative dose intensity in patients receiving adjuvant breast cancer chemotherapy. Proc Am Soc Clin Oncol 2001;20:394A.
5. Bohlius J, Reiser M, Schwarzer G, Engert A. Impact of granulocyte colony-stimulating factor (CSF) and granulocytemacrophage CSF in patients with malignant lymphoma: A systematic review. Br J Haematol 2003;122:413-23. (Pubitemid 36951625)
6. Repetto L, Biganzoli L, Koehne CH, et al. EORTC Cancer in the Elderly Task Force guidelines for the use of colonystimulating factors in elderly patients with cancer. Eur J Cancer 2003;39:2264-72. (Pubitemid 37214850)
7. Doorduijn JK, van der Holt B, Buijt I, et al. Prophylactic granulocyte colony-stimulating factor (G-CSF) added to CHOP in the treatment of elderly patients with aggressive non- Hodgkin's lymphoma (NHL). Final results of a multicenter phase 3 study. Ann Oncol 2002;13(Suppl. 2):28 (abstr 083).
8. Bjorkholm M, Osby E, Hagberg H, et al. Randomized trial of rmetHu granulocyte colony-stimulating factor (G-CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin's lymphoma. Blood 1999;95:599 (abstr 2665).
9. Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997;89:3974-9. (Pubitemid 27220941)
10. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70.
11. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205. (Pubitemid 46638957)
12. Lyman GH, Lyman CG, Sanderson RA, Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993;85: 488-93. (Pubitemid 23084095)
13. Lyman GH, Kuderer N, Greene J, Balducci L. The economics of febrile neutropenia: Implications for the use of colonystimulating factors. Eur J Cancer 1998;34:1857-64. (Pubitemid 28535432)
14. Silber JH, Fridman M, Shpilsky A, et al. Modeling the costeffectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J Clin Oncol 1998;16:2435-44. (Pubitemid 28309038)
15. Zagonel V, Babare R, Merola MC, et al. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann Oncol 1994;5(Suppl. 2):127-32. (Pubitemid 24061335)
16. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(8 Suppl.):IV-3-18.
17. Klabunde CN, Legler JM, Warren JL, et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. D. Ann Epidemiol 2007;17:584-90. (Pubitemid 47096709)
18. Rubin DB, Thomas N. Matching using estimated propensity scores: Relating theory to practice. Biometrics 1996;52:249-64. (Pubitemid 26125107)
19. Cochran WG. The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics 1968;24:295-313.
20. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-24.
21. Indurkhya A, Mitra N, Schrag D. Using propensity scores to estimate the cost-effectiveness of medical therapies. Stat Med 2006;25:1561-76.
22. Mitra N, Indurkhya A. A propensity score approach to estimating the cost-effectiveness of medical therapies from observational data. Health Econ 2005;14:805-15. (Pubitemid 41093977)
23. Zethraeus N, Johannesson M, Jönsson B, et al. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies. Pharmacoeconomics 2003;21: 39-48. (Pubitemid 36078491)
24. O'Brien BJ, Briggs AH. Analysis of uncertainty in health care cost-effectiveness studies: An introduction to statistical issues and methods. Stat Methods Med Res 2002;11:455-68. (Pubitemid 36096865)
25. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005;187:106-8. (Pubitemid 41139681)
26. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 2004;13:405-15. (Pubitemid 38660390)
27. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-87. (Pubitemid 34041389)
28. Severens JL, Brunenberg DE, Fenwick EA, et al. Costeffectiveness acceptability curves and a reluctance to lose. Pharmacoeconomics 2005;23:1207-14. (Pubitemid 41803317)
29. Clarke CA, Undurraga DM, Harasty PJ, et al. Changes in cancer registry coding for lymphoma subtypes: Reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev 2006;15:630-8.
30. Kritz FL. Cancer patients facing costly treatments can benefit from frank talks with doctors. February 16, 2009. Los Angeles Times.
31. Ozer H, Armitage JO, Bennett CL, et al. American Society of Clinical Oncology. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidencebased, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18:3558-85.
32. Cosler LE, Sivasubramaniam V, Agboola O, et al. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Value Health 2005;8:47-2. (Pubitemid 40293640)
33. Lyman GH. Balancing the benefits and costs of colonystimulating factors: A current perspective. Semin Oncol 2003;30(Suppl. 13):10-7. (Pubitemid 37140186)
34. Lyman GH. A predictive model for neutropenia associated with cancer chemotherapy. Pharmacotherapy 2000;20(7 Pt. 2):104S-11S. (Pubitemid 30460446)
35. Silber JH, Fridman M, Shpilsky A, et al. Modeling the costeffectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J Clin Oncol 1998;16:2435-44. (Pubitemid 28309038)
36. Dranitsaris G, Altmayer C, Quirt I. Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma. Pharmacoeconomics 1997;11:566-77. (Pubitemid 27283637)
37. Bohlius J, Herbst C, Reiser M, et al. Granulopoiesisstimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2008;Oct.8:CD003189.
38. Repetto L, Biganzoli L, Koehne CH, et al. EORTC Cancer in the Elderly Task Force guidelines for the use of colonystimulating factors in elderly patients with cancer. Eur J Cancer 2003;39:2264-72. (Pubitemid 37214850)
39. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205. (Pubitemid 46638957)
40. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEERMedicare data. Med Care 2002;40(8 Suppl.):IV-104-17.
41. Etzioni R, Riley GF, Ramsey SD, Brown M. Measuring costs: Administrative claims data, clinical trials, and beyond. Med Care 2002;40(6 Suppl.):III63-72.
42. Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Econ 2001;10:179-84.
43. Altman DG, Bland MJ. Statistics notes: Absence of evidence is not evidence of absence. BMJ 1995;311:485.